| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGFBP4 |
| Uniprot No | P22692 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-258aa |
| 氨基酸序列 | DEAIHCPPCSEEKLARCRPPVGCEELVREPGCGCCATCALGLGMPCGVYT PRCGSGLRCY PPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDEGDHPNNSFSPC SAHDRRCLQK HFAKIRDRSTSGGKMKVNGAPREDARPVPQGSCQSELHRALERLAASQSR THEDLYIIPI PNCDRNGNFHPKQCHPALDGQRGKCWCVDRKTGVKLPGGLEPKGELDCHQ LADSFREVDHHHHHH |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGFBP4重组蛋白的3篇示例文献(内容为假设性概括，仅供参考)：
1. **文献名称**：*Recombinant IGFBP4 inhibits tumor angiogenesis and growth via IGF signaling modulation*
**作者**：Kelley, M. et al.
**摘要**：研究通过重组IGFBP4蛋白调控IGF-1活性，发现其可抑制肿瘤血管生成并减缓小鼠模型中结直肠癌的生长。
2. **文献名称**：*Expression and functional analysis of IGFBP4 in cardiac development using recombinant protein*
**作者**：Kim, S. & Park, J.
**摘要**：利用大肠杆菌表达的重组IGFBP4蛋白，揭示其在心肌细胞分化和心脏发育中的调控作用，提示与先天性心脏病潜在关联。
3. **文献名称**：*High-yield production of bioactive recombinant IGFBP4 in E. coli*
**作者**：Smith, R. et al.
**摘要**：开发了一种高效表达和纯化重组IGFBP4蛋白的方法，验证其与IGF-1的结合活性，为大规模制备提供技术方案。
4. **文献名称**：*IGFBP4 regulates osteoblast apoptosis through caspase-dependent pathways*
**作者**：Jones, L. et al.
**摘要**：重组IGFBP4通过结合IGF-1调控成骨细胞凋亡，提示其在骨质疏松症治疗中的潜在应用价值。
如需真实文献，建议通过PubMed或Web of Science检索关键词“recombinant IGFBP4”或“IGFBP4 protein function”获取近期研究。
Insulin-like Growth Factor Binding Protein 4 (IGFBP4) is a member of the IGFBP family, which regulates the bioavailability and activity of insulin-like growth factors (IGFs) by binding to IGF-I and IGF-II. These growth factors play critical roles in cell proliferation, differentiation, and survival through the IGF/insulin signaling pathway. IGFBP4 modulates IGF actions by sequestering them in circulation or targeting tissues, thereby limiting their interaction with IGF receptors. Unlike some other IGFBPs, IGFBP4 lacks intrinsic signaling activity but can influence cellular processes indirectly through IGF-dependent or IGF-independent mechanisms, including interactions with extracellular matrix components or other proteins.
Recombinant IGFBP4 protein is produced using genetic engineering techniques, typically expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. It is widely used in research to investigate IGF-related pathways in physiology and disease. Studies have shown that IGFBP4 dysregulation is linked to metabolic disorders, cardiovascular diseases, and cancer. For example, it may act as a tumor suppressor by inhibiting IGF-driven oncogenesis, though conflicting evidence suggests context-dependent roles in tumor progression. In cardiovascular research, IGFBP4 has been associated with vascular calcification and atherosclerosis.
The recombinant protein serves as a tool for elucidating IGFBP4's structural-functional relationships, including its heparin-binding domains and protease cleavage sites, which determine its stability and IGF affinity. Additionally, it is explored for therapeutic potential, such as developing IGFBP4-based biomarkers or targeted therapies to modulate IGF signaling in pathological conditions. Its applications extend to in vitro assays, animal studies, and drug discovery platforms aiming to balance IGF system activity in diseases like diabetes or cancer. Ongoing research continues to uncover its complex regulatory networks and tissue-specific functions.
×
